H. Lundbeck A/S (Lundbeck) today announced that it has signed agreements with Zenobia Therapeutics (Zenobia) and Vernalis plc (Vernalis) which will provide Lundbeck with access to know-how relevant for making inhibitors for Leucine-rich repeat kinases.

Pfizer Inc. (NYSE: PFE) announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

H. Lundbeck A/S (Lundbeck) announced a revised agreement with its partner in China, Xian-Janssen Pharmaceuticals Ltd. (Xian-Janssen), that change the terms from the current license agreement for Lexapro® to a co-promotion agreement.

Amgen (Nasdaq: AMGN) announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint),

Genzyme Corp. (NASDAQ: GENZ) reiterated the unanimous recommendation of its board of directors that shareholders continue to reject the sanofi-aventis $69-per-share tender offer, which has been extended until January 21, 2011.

Bayer HealthCare is building a new facility center in Wuppertal on an area of some 1,000 square meters for the biotechnological production of pharmaceuticals to be used in clinical trials. The investment in this project amounts to 35 million Euros, thereby enabling Bayer to expand its competences in the area of biological products.

Pfizer Inc. (NYSE: PFE) announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program.